Drug Trial Radar · NCT07391332
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a Pilot Study
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Jul 8, 2029
Study completion Jul 8, 2029
Sponsor
- Lead sponsor
- Nantes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The PASSENGER project aims to conduct a pilot feasibility study of the implementation of a randomized clinical trial on psilocybin-assisted psychotherapy for the treatment of gambling disorder. Feasibility will be assessed by estimating the ability to retain participants until the end of the protocol. Other objectives of the study will be to generate preliminary efficacy data, identify clinical factors potentially associated with the intensity of the psychedelic experience (which determines the expected therapeutic effect), and conduct a preliminary assessment of the safety of the treatment under study.
Conditions
- Gambling Disorder
Interventions
Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate)Drug
The first session of psilocybin PEX010 administration will use a moderately high dose of psilocybin, i.e., 25 mg. The dose may be increased to 40 mg during the second administration session in the experimental group, depending on the response during the previous session, as assessed by the Mystical Experience Questionnaire-30 (MEQ-30).
Psychotherapy assisted by low-dose psilocybin (1 mg)Drug
The first session of psilocybin PEX010 administration will use a very low dose of 1 mg in the control group. During the second administration session, the dose will be maintained at 1 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Protocol completion rateTime frame: End of study (33 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nantes University Hospital
Nantes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.